This roundtable series explores tyrosine kinase inhibitor use and other treatments for patients with renal cell carcinoma, as discussed by participants at virtual live events.
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other HistologiesJuly 15th 2022
During a live virtual event, Ulka N. Vaishampayan, MBBS, discussed the choice of first-line therapy for clear cell renal cell carcinoma and whether the approach to treatment would change with other disease histologies.
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?August 29th 2022
Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.
Choosing Frontline RCC Therapy After Detecting Metastases in Patient Under ObservationSeptember 12th 2022
During a Targeted Oncology case-based roundtable event, Sumanta K. Pal, MD, discussed the choice of frontline therapy for a favorable-risk patient with advanced clear cell renal cell carcinoma.
Comparing Physician Experience With Trial Data for Frontline RCC RegimensOctober 3rd 2022
During a live virtual event, Sumanta K. Pal, MD, discussed with participants how their experience with immunotherapy and tyrosine kinase inhibitor therapies aligned with the data from pivotal clinical trials. This is the second of 2 articles based on this event.
Physicians Discuss Potential of Frontline Triplet Regimens for RCCJanuary 27th 2023
During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.
Opinions on the Optimal Role of Ipilimumab/Nivolumab in RCCFebruary 13th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Alan Tan, MD, discussed with participants their experiences with frontline regimens for advanced renal cell carcinoma, and potential trials that could optimize the use of immunotherapy and tyrosine kinase inhibitors. This is the second of 2 articles based on this event.